Linklaters (Washington)

Jeffrey Schmidt

Linklaters (Washington)
Lawyer (Partner)

Jeff joined Linklaters in October 2008 after serving almost three years as Director of the Bureau of Competition of the Federal Trade Commission. As Director, he was responsible for the supervision of the FTC’s antitrust enforcement in all merger and non-merger cases. The 300-member Bureau of Competition conducts antitrust reviews of a wide range of industries, including oil and gas, chemicals, pharmaceuticals, food and beverage and consumer products. Prior to joining the FTC, Jeff was in private practice as a partner at Pillsbury Winthrop. His practice focused on merger matters, civil antitrust litigation and cartel enforcement proceedings. Jeff is an active member of the Antitrust Section of the American Bar Association and co-chair of its Economics Committee. He is a former chair of the State Action/Noerr-Pennington Committee and Editor of the ABA Antitrust Section’s monograph on the Noerr-Pennington doctrine.

Linked authors

Linklaters (London)
Linklaters (Düsseldorf)
Linklaters (New York)
Linklaters (London)
Linklaters (London)


1626 Bulletin

Antonia Sherman, Jeffrey Schmidt, Thomas A. McGrath The US DoJ takes action against CEO of cable television services company for failure to comply with HSR Act in connection with acquisition of vested shares (Roberts / Comcast)


The US antitrust authorities recently took action against an executive for violation of the Hart-Scott-Rodino Act (the “HSR Act”) in connection with the acquisition of stock as part of his compensation, resulting in a $500,000 fine. The HSR Act requires acquirers of certain voting securities (...)

Anne Wachsmann, Christopher Bellamy QC, Gerwin Van Gerven, Jeffrey Schmidt, Olivier d’Ormesson, Robert Gavin The EU Court of Justice confirms that the Commission must assess whether an agreement to limit parallel trade in medicines has pro-competitive benefits (GlaxoSmithKline)


On 6 October, the European Court of Justice (‘ECJ’) issued another “score draw” judgment in the long-running battle of R&D-based pharmaceutical companies to limit parallel trade in medicines across the EU. While the ECJ required the European Commission to conduct an in-depth examination of (...)

3977 Review

Send a message